2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.17 Odintsov

PP01.17 Odintsov - Poster

Pdf Summary

The study focuses on lung squamous cell carcinoma (LUSC), the second most common lung cancer type globally, known for having fewer targetable genetic changes compared to other types. The research investigates the clinicopathologic and genomic features of LUSC with targetable genetic alterations. Out of 503 cases studied, 45 showed conventional mitogenic driver alterations like KRAS and MET, making up 8.9% of the cases, with a majority being targetable with FDA-approved therapies for non-small cell lung cancer (NSCLC). MET alterations were more prominent in LUSC compared to lung adenocarcinoma. The study also highlights MET exon 14 skipping mutations as a distinct subset within LUSC, predominantly found in patients with a history of never smoking or light smoking. Patients with MET exon 14 skipping mutations responded well to MET tyrosine kinase inhibitors, with disease control seen in 4 out of 7 patients. The research underscores the significance of next-generation tumor sequencing in managing LUSC, shedding light on potential targeted treatment options for this type of lung cancer.

Keywords

lung squamous cell carcinoma

LUSC

genetic alterations

KRAS

MET

FDA-approved therapies

non-small cell lung cancer

MET exon 14 skipping mutations

tyrosine kinase inhibitors

next-generation tumor sequencing